You are here: Industry Insights > Psoriasis

News List

Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Plaque Psoriasis Accepted by FDA and Validated by European Medicines Agency AmericanPharmaceuticalReview
December 01, 2021
Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for deucravacitinib for ...
Innovent Announces First Patient Dosed in a Phase 2 Clinical Trial of IBI112 (IL-23 Monoclonal Antibody) in Patients with Moderate-to-severe Plaque Psoriasis prnasia
September 28, 2021
Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer...
Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70 prnasia
July 02, 2021
Lipidor AB (publ) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market drug ...
Lipidor licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70 firstwordpharma
July 02, 2021
Lipidor AB (publ) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market drug.
Sonelokimab shows promise in Phase II psoriasis trial europeanpharmaceuticalreview
May 08, 2021
In the trial, 57 percent of patients with moderate to severe psoriasis treated with 120mg of sonelokimab achieved total skin clearance in 24 weeks.
BMS’ deucravacitinib tops Otezla in two psoriasis studies pharmatimes
April 27, 2021
Bristol Myers Squibb’s investigational selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib topped Amgen’s Otezla in two Phase III psoriasis studies.
Lipidor - update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis prnasia
April 23, 2021
Lipidor AB (publ) provides an update on the planned Phase III study of the company's drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, Lipidor submitted an application to the Indian Medical Products Agency for ...
BMS’ deucravacitinib beats Otezla in psoriasis study pharmatimes
February 05, 2021
Bristol Myers Squibb’s investigative drug deucravacitinib has demonstrated positive results in a Phase III trial, including showing superiority over Amgen’s Otezla (apremilast).
IPC Statement On SARS-CoV-2 Vaccines And Psoriasis prnasia
December 03, 2020
The SARS-CoV-2 pandemic continues to have a considerable impact on the provision of appropriate care to people with psoriasis.
Bristol Myers Squibb’s psoriasis med hits the mark in phase III pharmatimes
November 06, 2020
Bristol Myers Squibb’s tyrosine kinase 2 (TYK2) inhibitor deucravacitinib outperformed Amgen’s Otezla in a phase III psoriasis study, the pharma company revealed yesterday.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page